We have chosen to dedicate this newsletter to NeoNavia's exciting clinical program, which will enable us to strengthen our profile, as it is in a clinical setting. Customers are always keen to see a company's investment in clinical programs, as it demonstrates the belief and commitment in the product long-term.
We also have plans to start a Registry on the use of NeoNavia, in Germany, which will allow us to gather real world data for our product. Such real world data and evidence appeal to both physicians and authorities, as it can help support NeoNavia, when looking at patient outcomes and health economics.
- Read about the UK COMPULSE study
- Watch our June Q&A session with Redeye